Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease
Open Access
- 1 November 2010
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 105 (7), 918-924
- https://doi.org/10.1590/s0074-02762010000700014
Abstract
Therapeutic failure of benznidazole (BZ) is widely documented in Chagas disease and has been primarily associated with variations in the drug susceptibility of Trypanosoma cruzi strains. In humans, therapeutic success has been assessed by the negativation of anti-T. cruzi antibodies, a process that may take up to 10 years. A protocol for early screening of the drug resistance of infective strains would be valuable for orienting physicians towards alternative therapies, with a combination of existing drugs or new anti-T. cruzi agents. We developed a procedure that couples the isolation of parasites by haemoculture with quantification of BZ susceptibility in the resultant epimastigote forms. BZ activity was standardized with reference strains, which showed IC50 to BZ between 7.6-32 mu M. The assay was then applied to isolates from seven chronic patients prior to administration of BZ therapy. The IC50 of the strains varied from 15.6 +/- 3-51.4 +/- 1 mu M. Comparison of BZ susceptibility of the pre-treatment isolates of patients considered cured by several criteria and of non-cured patients indicates that the assay does not predict therapeutic outcome. A two-fold increase in BZ resistance in the post-treatment isolates of two patients was verified. Based on the profile of nine microsatellite loci, sub-population selection in non-cured patients was ruled out.Keywords
This publication has 31 references indexed in Scilit:
- Trypanosoma cruzi maxicircle heterogeneity in Chagas disease patients from BrazilInternational Journal for Parasitology, 2009
- Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitationsMemórias do Instituto Oswaldo Cruz, 2009
- The Treatment of Chagas Disease (South American Trypanosomiasis)Annals of Internal Medicine, 2006
- Long term evaluation of etiological treatment of chagas disease with benznidazole.Revista do Instituto de Medicina Tropical de São Paulo, 2002
- A Critical Review on Chagas Disease ChemotherapyMemórias do Instituto Oswaldo Cruz, 2002
- Immunological and Clinical Evaluation of Chagasic Patients Subjected to Chemotherapy during the Acute Phase ofTrypanosoma cruziInfection 14–30 Years AgoThe Journal of Infectious Diseases, 2000
- Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infectionThe Lancet, 1996
- Hemocultures for the parasitological diagnosis of human chronic Chagas' diseaseRevista da Sociedade Brasileira de Medicina Tropical, 1989
- Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas diseaseTransactions of the Royal Society of Tropical Medicine and Hygiene, 1987
- In vitro screens in the experimental chemotherapy of leishmaniasis and trypanosomiasisParasitology Today, 1986